Dr. Hamzah Alkhazaleh
Associate Professor, University of Dubai
"As a researcher specializing in artificial intelligence and computational optimization, I am honored to lead the GAP-AD project, which introduces a pioneering approach to early Alzheimer’s detection through the integration of graphene-based biosensors, advanced deep learning models, and metaverse-enabled diagnostics. This project aligns with my commitment to leveraging AI for transformative healthcare solutions, addressing critical challenges in non-invasive, cost-effective, and scalable diagnostics. Through interdisciplinary collaboration and cutting-edge innovation, we aim to redefine early disease detection, enhance patient outcomes, and position Dubai as a global leader in next-generation medical technologies."
The proposed Point-of-Care (PoC) device leverages the high sensitivity and conductivity of graphene to detect key AD biomarkers, such as amyloid-beta peptides and tau proteins, in non-invasive samples like blood and saliva. Complemented by advanced deep learning algorithms, the device enables precise biomarker analysis, disease onset prediction, and progression monitoring, significantly improving diagnostic accuracy. Additionally, the integration of a metaverse-based virtual platform provides an immersive environment for clinician-patient engagement, facilitating visualizations of disease progression and simulated treatment plans.
The project aligns with the Dubai RDI Grant Program’s strategic goals in the Health and Life Sciences sector, addressing critical global healthcare challenges through innovative and accessible diagnostic methods. It promotes Dubai’s vision of fostering cutting-edge medical technologies and becoming a global leader in healthcare innovation. By integrating cross-disciplinary expertise in artificial intelligence, biosensing, and virtual healthcare, the project directly contributes to advancing personalized medicine and scalable healthcare solutions.
Collaboration between institutions such as the University of Dubai, Al Amal Hospital for Mental Health, the University of Sharjah, Qatar University, and Macquarie University forms a robust multidisciplinary research network. Key deliverables include a graphene-based biosensor, deep learning models for biomarker analysis, an immersive metaverse platform, and validated clinical trials to pave the way for commercialization and training programs.
This project sets new benchmarks in non-invasive, cost-effective AD diagnostics, enhancing accessibility and patient care. It is poised to significantly impact Dubai’s research and development ecosystem, elevate its global reputation, and contribute to the advancement of Alzheimer’s detection and treatment on a worldwide scale.